In a recently published large-scale transcriptomic profiling of tumor microenvironments in 5,490 patients with NSCLC, ALK+ tumors were associated with high PD-L1 (>50%) expression (40% vs. 47% for KRAS-mutated vs. 18% for EGFR-mutated tumors; P < 0.001) when compared with EGFR- and KRAS-mutated tumors. This evidence concerns the gene ALK and non-small cell lung carcinoma.